VRTX R&D Expense Growth
Vertex Pharmaceuticals · R&D Expense Growth
VRTX R&D Expense Growth
Latest reported3.40%period ending
VRTX FY R&D Growth (YoY) (0.00% → 3.40%)
Latest values, visible window
High-resolution chart · PNG
VRTX r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 3.3992% | |
| 14.7776% | |
| 19.0941% | |
| -12.956% | |
| 66.769% | |
| 4.2745% | |
| 23.8666% | |
| 6.9341% | |
| 26.4329% | |
| 5.1718% | |
| 16.4422% | |
| -6.887% | |
| 13.9668% | |
| 13.9152% | |
| 11.0273% | |
| 15.7497% | |
| 6.6615% | |
| 0.6311% | |
| 38.0242% | |
| 49.5586% | |
| 29.3388% | |
| -3.7438% | |
| -1.6659% | |
| 36.5534% | |
| 75.0721% | |
| 17.6191% | |
| 22.9983% | |
| 13.7597% | |
| 46.5909% | |
| -15.1807% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |